Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.80

€3.80

-6.750%
-0.295
-6.750%
€8.50

€8.50

 
Latest predictions
€8.00
18.01.21
buy
-
28.10.20
€5.00
16.03.20
buy
-
11.01.20
buy
€12.00
20.09.19
buy
€9.00
15.07.19
buy
Your prediction

Financial data and news for Medigene

sharewise wants to provide you with the best news and tools for Medigene, so we directly link to the best financial data sources.

News

Medigene AG: Medigene provides Q3 2020 update

Business news for the stock market

 

Planegg/Martinsried (12.11.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development

Medigene AG: Oral and poster presentations on Medigene's clinical research at ASH conference

Business news for the stock market

 

Planegg/Martinsried (05.11.2020) - 5 November 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development

 

Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the

Medigene AG: Three Medigene poster presentations at SITC Annual Meeting

 

Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Medigene expands patent protection of its technologies

 

Planegg/Martinsried (06.10.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has

Medigene AG: Medigene participates at upcoming virtual conferences

Martinsried/ Munich (28.09.2020) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that

Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA

Business news for the stock market

Planegg/Martinsried (22.09.2020) - 22 September 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene AG: Further encouraging results from long-term follow-up of AML patients in DC vaccine trial

Business news for the stock market

 

Planegg/Martinsried (08.02.2021/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the

Focus on solid tumors - Discontinuation of MDG1021 development program

Conference call today, 3.00 pm CET (9.00 am ET)

 

Planegg/Martinsried (28.01.2021) - 28 January 2021. The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical

Medigene AG: Medigene expands patent protection of its technologies in key markets, the USA and Europe

Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was

Medigene AG: Participation at upcoming virtual conferences

 

Planegg/Martinsried (21.12.2020) - 21 December 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Dr. Anthony Man appointed to Supervisory Board

 

Planegg/Martinsried (16.12.2020) - The Executive Management Board and the Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company

Medigene AG: PRAME expression and HLA genotype screening in AML and MDS patients

Poster at ASH Annual Meeting 2020, 5-8 December 2020

 

Planegg/Martinsried (07.12.2020/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company f

Medigene AG: Detailed analysis from Medigene's completed Phase I/II DC vaccine in AML patients presented orally at ASH 2020

Planegg/Martinsried (07.12.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, is